There are few fully accrued contemporary studies that randomize patients to surgery or radiation for curative treatment of a solid tumor. Featured in the April 1 Oncology Scan, the ORATOR 1 clinical trial is one such study of head and neck cancer that compared primary transoral robotic surgery (TORS) versus radiation therapy (RT) for treatment of oropharynx cancer, with a patient reported quality of life primary endpoint. Join Red Journal Associate Editor Danielle Margalit, MD as she discusses the trial with authors Anthony Nichols, MD, FRCSC, FACS and David Palma, MD, PhD, FRCPC, and with special guest, Kate Hutcheson, PhD, speech pathologist and expert in patient reported outcome assessment. The ORATOR 1 trial provides information for patient counseling and decision-making when considering the 'trade-offs' of different treatment modalities.
